Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Douglas Ball

Douglas Wilmot Ball, MD

Associate Professor of Medicine
Male
Appointment Phone

410-955-9270

Main Location

Johns Hopkins Outpatient Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Medicine
  • Associate Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Expertise

Endocrine Oncology, Endocrinology, Thyroid Cancer, Thyroid Diseases

Research Interests

anaplastic thyroid cancer; differentiated thyroid cancer; medullary thyroid cancer

Languages

  • English
Additional Resources +
  • Education +

    Training

    • George Washington University School of Medicine (Washington DC) (1984)

    Certifications

    • American Board of Internal Medicine / Internal Medicine (1987)
  • Research & Publications +

    Research Summary

    Dr. Ball is an endocrinologist who is involved in clinical trials and pre-clinical laboratory studies in thyroid cancer.  Dr. Ball's clinical trials have included protocols for advanced radioiodine-refractory differentiated thyroid cancer and medullary thyroid cancer.  These studies are performed in collaboration with research staff in the upper aero-digestive group in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.  Dr. Ball is associate protocol chair and a member of the board of directors of the International Thyroid Oncology Group (ITOG).  He's developed national trials through this cooperative group.  A focus of these clinical trials is the role of multikinase inhibitors, and inhibitors of the RAS-RAF-MAPK and PI3K pathways.

    In pre-clinical research, Dr. Ball collaborates with Dr. Nelkin, Dr. Agrawal and others in the Cancer Biology division of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.  The principal areas of this research include pathogenesis and mechanisms of treatment resistance in medullary thyroid cancer, and pathogenesis and immune-directed therapy of anaplastic thyroid cancer.  Recent studies have also focused on targeting the RAS-RAF-MAPK and PI3K pathways in differentiated thyroid cancer.  This work is supported by the NIH and American Cancer Society.

    Selected recent publications:

    1. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts N, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SPA, Toledo RA, Morris LGT, Ghossein R, Fagin JA, Chan TA, Velculescu VA, Vogelstein B, Kinzler KW, PapadopoulosN, Nelkin BD, and Ball DW. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98:E364-9, 2013.
    2. Elisei R, Schlumberger M, Mueller S, Schoffski P, Brose M, Shah M, Licitra L, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen E, Wirth L, Ali H, Hessel C, Yaron Y, Ball D Nelkin B, Sherman S. Cabozantinib in Progressive Medullary Thyroid Cancer. J Clin Oncol, 31:3639-46, 2013.
    3. Jin N, Jiang T, Rosen DN, Nelkin BD, Ball DW . Synergistic action of a RAF inhibitor and dual PI-3 Kinase / mTOR inhibitor in thyroid cancer. Clin Can Res 17:6482-9, 2011.
    4. Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball DW, Doyle LA, Chen H, Ye X, Azad N. A Phase I trial of vertical inhibition of IGF signaling using cixutumumab, an anti-IGF1-R antibody, and selumetinib, a MEK 1/2 inhibitor, in patients with advanced solid tumors, British Journal of Cancer, 2014, in press.

    Selected Publications

      1. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts N, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SPA, Toledo RA, Morris LGT, Ghossein R, Fagin JA, Chan TA, Velculescu VA, Vogelstein B, Kinzler KW, PapadopoulosN, Nelkin BD, and Ball DW. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98:E364-9, 2013.
      2. Elisei R, Schlumberger M, Mueller S, Schoffski P, Brose M, Shah M, Licitra L, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen E, Wirth L, Ali H, Hessel C, Yaron Y, Ball D Nelkin B, Sherman S. Cabozantinib in Progressive Medullary Thyroid Cancer. J Clin Oncol, 31:3639-46, 2013.
      3. Jin N, Jiang T, Rosen DN, Nelkin BD, Ball DW . Synergistic action of a RAF inhibitor and dual PI-3 Kinase / mTOR inhibitor in thyroid cancer. Clin Can Res 17:6482-9, 2011.
      4. Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball DW, Doyle LA, Chen H, Ye X, Azad N. A Phase I trial of vertical inhibition of IGF signaling using cixutumumab, an anti-IGF1-R antibody, and selumetinib, a MEK 1/2 inhibitor, in patients with advanced solid tumors, British Journal of Cancer, 2014, in press.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Outpatient Center
    601 N. Caroline Street
    Baltimore, MD 21287
    Phone: 410-502-4926
    Appointment Phone: 410-955-9270
    Location Map

    Department/Division

    • Medicine - Endocrinology, Diabetes, & Metabolism

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer